Brachytherapy versus prostatectomy in localized prostate cancer: Results of a French multicenter prospective medico-economic study
- Department of Medical Information, Institut Curie, Paris (France)
- Department of Oncology/Radiotherapy, Institut Curie, Paris (France)
- Department of Radiotherapy, Centre Leon Berard, Lyon (France)
- Department of Radiotherapy, Centre Alexis Vautrin, Nancy (France)
- Department of Radiotherapy, Centre Claudius Regaud, Toulouse (France)
- Department of Urology, Hopital Cochin, Paris (France)
- Department of Radiotherapy, Centre Hospitalier Universitaire, Poitiers (France)
- Department of Radiotherapy, Institut Paoli-Calmettes, Marseille (France)
- Department of Radiotherapy, Clinique Hartmann, Neuilly sur Seine (France)
Purpose: To prospectively compare health-related quality of life (HRQOL), patient-reported treatment-related symptoms, and costs of iodine-125 permanent implant interstitial brachytherapy (IB) with those of radical prostatectomy (RP) during the first 2 years after these treatments for localized prostate cancer. Methods and Materials: A total of 435 men with localized low-risk prostate cancer, from 11 French hospitals, treated with IB (308) or RP (127), were offered to complete the European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire QLQ-C30 version 3 (EORTC QLQ-C30) and the prostate cancer specific EORTC QLQ-PR25 module before and at the end of treatment, 2, 6, 12, 18, and 24 months after treatment. Repeated measures analysis of variance and analysis of covariance were conducted on HRQOL changes. Comparative cost analysis covered initial treatment, hospital follow-up, outpatient and production loss costs. Results: Just after treatment, the decrease of global HRQOL was less pronounced in the IB than in the RP group, with a 13.5 points difference (p < 0.0001). A difference slightly in favor of RP was observed 6 months after treatment (-7.5 points, p = 0.0164) and was maintained at 24 months (-8.2 points, p = 0.0379). Impotence and urinary incontinence were more pronounced after RP, whereas urinary frequency, urgency, and urination pain were more frequent after IB. Mean societal costs did not differ between IB ( Euro 8,019 at T24) and RP ( Euro 8,715 at T24, p = 0.0843) regardless of the period. Conclusions: This study suggests a similar cost profile in France for IB and RP but with different HRQOL and side effect profiles. Those findings may be used to tailor localized prostate cancer treatments to suit individual patients' needs.
- OSTI ID:
- 20944733
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 67, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2006.10.011; PII: S0360-3016(06)03247-0; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Health-Related Quality of Life up to Six Years After {sup 125}I Brachytherapy for Early-Stage Prostate Cancer
Promising Long-Term Health-Related Quality of Life After High-Dose-Rate Brachytherapy Boost for Localized Prostate Cancer